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Since the first isolation of Candida auris in 2009, scien-
tific community has witnessed an exponential emergence
of infection episodes and outbreaks in different world
regions [1]. According to the Centers for Disease Control
and Prevention (CDC), 560 cases of C. auris infections have
been notified in the United States as 31 January 2019. It is
likely that many cases are missed, due to its misidentifica-
tion with other non-albicans Candida spp. (e.g., C. haemu-
lonii) by common microbiological diagnostic methods
(https://www.cdc.gov/fungal/diseases/candidiasis/tracking-c
-auris.html). Most of the reports occurred in critically ill
adults, with risk factors for invasive fungal infections, such
as immunosuppression, surgery, or indwelling catheters.
The most common form of infection was candidemia, with
a crude mortality of nearly 30%, but up to 70% in some re-
ports [2].
Despite implementation of countermeasures to limit
colonization and infections in intensive care units (ICUs),
cases continue to be reported, with a tendency to an
endemic pattern [3]. This reflects the ability of C. auris to
persist in clinical environment, facilitating its transmission
within critical care setting. Multidrug-resistant (MDR) pat-
tern and has been frequently observed (around 40%) with
serious and complex consequences for antifungal therapy
[4].
In view of C. auris progressive spread and treatment
concerns, attention should be focused on the following
A.U.R.I.S. major issues (Fig. 1):
1. Worldwide Alert
2. AntifUngal treatment resistance
3. Resilience and mechanisms of transmission
4. Implementation of infection prevention and control
measures
5. Surveillance
Worldwide Alert
Following the first isolation in Japan, cases have been
reported in several countries in five continents. Although
uncommon for fungi, C. auris has the ability to cause
outbreaks, as seen in India, the UK, Spain, the USA,
Venezuela, Colombia, and South Africa [1]. It is still de-
bated whether C. auris emerged in one region with subse-
quent spreading to others, or if it emerged independently
across different countries. Evidence from genomic sequen-
cing demonstrates different clades of C. auris show strong
geographic structure, with independent emergence in East
and South Asia, Africa, and South America [1, 5, 6].
AntifUngal treatment resistance
To date, there are not established minimum inhibitory
concentrations (MICs) breakpoints for susceptibility testing
of C. auris. Antifungal susceptibility data from three conti-
nents demonstrated that nearly 40% were MDR, with
strains being resistant to fluconazole (90%), amphotericin B
(30–40%) and echinocandins (5–10%). Moreover, a small
percentage were also resistant to all antifungals actually
available [4, 6]. C. auris demonstrates a high propensity to
develop antifungal resistance under selective pressure. Re-
cent studies demonstrated mutations in ERG11 (encoding
lanosterol demethylase, the target of azoles) and FKS1
genes (encoding 1,3-beta-glucan synthase, the target of
echinocandins) [1, 7].
The recommended antifungals for C. auris treat-
ment are mainly based on in vitro testing and on the
most frequently retrieved resistance profiles. Echino-
candins are the recommended first-line treatment,
pending specific susceptibility testing. Lipid formula-
tion of amphotericin B should be an alternative in
patients not responding to echinocandins. Close
monitoring to early detect therapeutic failures and
evolution of antifungal resistance is needed. New
antifungals (e.g., SCY-078, APX001A/APX001, and
rezafungin) have been tested with success but they
are not available to date for clinical use [1].
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Resilience and mechanisms of transmission
Unlike others Candida species, C. auris can colonize differ-
ent anatomical sites (e.g., skin, skin, rectum, axilla, stool)
and contaminate hospital equipment and surfaces, creating
a vicious cycle of acquisition, spreading, and infection, par-
ticularly in ICUs. Indeed, bed, chairs, and monitoring tools
(e.g., pulse oximeters, temperature probes) were contami-
nated during outbreaks [8]. Recently, Eyre et al. [9] pub-
lished the results of a patients’ and hospital environmental
screening program in Oxford, UK, after 70 patients (66 ad-
mitted to a neuro-ICU) were identified as being colonized
or infected by C. auris. Seven patients developed an inva-
sive infection during hospital stay. C. auris was detected
mainly on skin-surface axillary temperature probes and
other reusable tools. In patients monitored with
skin-surface temperature probes, the risk of C. auris infec-
tion/colonization was seven times higher. Adoption of spe-
cific bundles of infection control had no significant effects
until removal of the temperature probes [9].
Recent studies have confirmed that C. auris can form
biofilms, with a high variation of capacity of production
depending on the C. auris strain considered [10]. Biofilm
may present reduced susceptibility to hydrogen peroxide
and chlorhexidine [11].
Quaternary ammonium compounds and cationic surface-
active products seem to be ineffective against C. auris.
Chlorine-based products appear to be the most effective for
environmental surface disinfection [12]. Chlorine-based
disinfectants (at a concentration of 1000 ppm), hydrogen-
peroxide, or other disinfectants with documented fungicidal
activity are recommended for environmental cleaning by
the European CDC (ECDC) [13].
Implementation of infection prevention and
control measures
CDC and ECDC released recommendations for C. auris
case and outbreak management [13]. Usually, outbreaks
follow an exponential increase in the number of affected
patients. It is mandatory to trace contacts with the aim
to achieve early identification and screening of possible
colonized patients that might be responsible for persist-
ence of C. auris. Patients potentially or already colonized
should be placed in single rooms with contact isolation
precautions. Screening should be applied for contacts
and patients previously hospitalized in healthcare
settings where C. auris isolation was confirmed. Hand
hygiene (with alcohol or chlorhexidine hand rubs), wear-
ing of protective clothing, and skin and environmental/
equipment decontamination should be performed to
prevent ongoing transmission.
Global Surveillance
Aiming to support implementation measures on global
surveillance on antimicrobial resistances, in 2016, the
World Health Organization [14] launched the Global
Resistance Surveillance System (GLASS). The emergence
of C. auris and progressive spread of infections caused
by other resistant pathogens has strengthened the need
for a surveillance network for antimicrobial resistance
globally for critically ill patients’ safety.
Fig. 1 Major issues related to Candida auris. Major issues related to Candida auris described with A.U.R.I.S. outline. MDR, multidrug resistant; ICU,
intensive care unit
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It is hard to predict future C. auris diffusion. There
will be outbreaks also in countries in which C. auris has
been not reported yet? Will new MDR clones continue
to emerge? Will we be able to apply effective antifungal
stewardship programs and control measures? By now,
global surveillance, improving knowledge, and taking
care of the A.U.R.I.S. major issues may be the best ways
to face C. auris challenge.
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